Novo Nordisk’s Rybelsus Now First Oral GLP-1 RA In Europe With Proven Heart Health Impact

All NewsSeptember 15, 2025

EMA approved Rybelsus’ label update after the SOUL trial showed it cuts heart attack, stroke, and death by 14% in high-risk type 2 diabetes patients.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent